SDP enters MOU worth potential $3bn for option to buy up to 11 Roivant vants; later signs definitive agreement, then completes M&A
Through a non-binding memorandum of understanding (MOU), Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. plan to forge an alliance involving the clinical-stage assets of multiple Roivant biopharmaceutical divisions (known as vants). The potential partners will conduct due diligence and expect to sign a definitive agreement by the end of October 2019.
- Includes Equity
- Includes M&A Option
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.